TriangleNCT01582061 · OUTCOME
Percent Change From Baseline in Insulin Growth Factor - 1 (IGF - 1) Values
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- percent change of ng/ml
- Interval / dispersion
- Standard Deviation
- Time frame
- Baseline, week 12, 24 and 48
What was measured
Descriptive summary of the effect of pasireotide on IGF-1
Analysis population: Number of patients with available data differed at visits
Groups in this outcome
Pasireotide 600 μg
Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 600 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 600 μg for glucose impaired metabolism patients. Mean daily dose category is defined: 600 μg bid group includes all patients whose mean daily dose \< 1500 μg /day.
Pasireotide 900 μg
Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg. Mean daily dose category is defined : 900 μg bid group includes all patients whose mean daily dose ≥ 1500 μg /day
All Patients
Patients received pasireotide 600 μg or 900 μg BID
| Group | Source count |
|---|---|
| Pasireotide 600 μg | 48 |
| Pasireotide 900 μg | 53 |
| All Patients | 101 |
Reported measurements
Week 12
| Group | Source count |
|---|---|
| Pasireotide 600 μg | 34 |
| Pasireotide 900 μg | 44 |
| All Patients | 78 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Pasireotide 600 μg | -53.4 | 23.66 | Not reported | Not reported | Not reported |
| Pasireotide 900 μg | -57.8 | 23.93 | Not reported | Not reported | Not reported |
| All Patients | -55.9 | 23.76 | Not reported | Not reported | Not reported |
Week 24
| Group | Source count |
|---|---|
| Pasireotide 600 μg | 23 |
| Pasireotide 900 μg | 29 |
| All Patients | 52 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Pasireotide 600 μg | -49.2 | 26.56 | Not reported | Not reported | Not reported |
| Pasireotide 900 μg | -56.2 | 26.55 | Not reported | Not reported | Not reported |
| All Patients | -53.1 | 26.53 | Not reported | Not reported | Not reported |
Week 48
| Group | Source count |
|---|---|
| Pasireotide 600 μg | 16 |
| Pasireotide 900 μg | 21 |
| All Patients | 37 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Pasireotide 600 μg | -41.8 | 35.72 | Not reported | Not reported | Not reported |
| Pasireotide 900 μg | -52.1 | 21.87 | Not reported | Not reported | Not reported |
| All Patients | -47.6 | 28.71 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 23.66
- value
- -53.4
- group Id
- OG001
- spread
- 23.93
- value
- -57.8
- group Id
- OG002
- spread
- 23.76
- value
- -55.9
- denoms
- counts
- group Id
- OG000
- value
- 34
- group Id
- OG001
- value
- 44
- group Id
- OG002
- value
- 78
- units
- Participants
- title
- Week 12
- categories
- measurements
- group Id
- OG000
- spread
- 26.56
- value
- -49.2
- group Id
- OG001
- spread
- 26.55
- value
- -56.2
- group Id
- OG002
- spread
- 26.53
- value
- -53.1
- denoms
- counts
- group Id
- OG000
- value
- 23
- group Id
- OG001
- value
- 29
- group Id
- OG002
- value
- 52
- units
- Participants
- title
- Week 24
- categories
- measurements
- group Id
- OG000
- spread
- 35.72
- value
- -41.8
- group Id
- OG001
- spread
- 21.87
- value
- -52.1
- group Id
- OG002
- spread
- 28.71
- value
- -47.6
- denoms
- counts
- group Id
- OG000
- value
- 16
- group Id
- OG001
- value
- 21
- group Id
- OG002
- value
- 37
- units
- Participants
- title
- Week 48
- denoms
- counts
- group Id
- OG000
- value
- 48
- group Id
- OG001
- value
- 53
- group Id
- OG002
- value
- 101
- units
- Participants
- description
- Descriptive summary of the effect of pasireotide on IGF-1
- dispersion Type
- Standard Deviation
- groups
- description
- Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 600 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 600 μg for glucose impaired metabolism patients. Mean daily dose category is defined: 600 μg bid group includes all patients whose mean daily dose \< 1500 μg /day.
- id
- OG000
- title
- Pasireotide 600 μg
- description
- Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg. Mean daily dose category is defined : 900 μg bid group includes all patients whose mean daily dose ≥ 1500 μg /day
- id
- OG001
- title
- Pasireotide 900 μg
- description
- Patients received pasireotide 600 μg or 900 μg BID
- id
- OG002
- title
- All Patients
- param Type
- MEAN
- population Description
- Number of patients with available data differed at visits
- reporting Status
- POSTED
- time Frame
- Baseline, week 12, 24 and 48
- title
- Percent Change From Baseline in Insulin Growth Factor - 1 (IGF - 1) Values
- type
- SECONDARY
- unit Of Measure
- percent change of ng/ml
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice